Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
65
VERV Quote, Financials, Valuation and Earnings
Last price:
$10.96
Seasonality move
:
1.05%
Day range:
$10.93 - $11.05
52-week range:
$2.86 - $11.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.91x
P/B ratio:
2.06x
Volume:
5.6M
Avg. volume:
6.4M
1-year change:
45.81%
Market cap:
$976.1M
Revenue:
$32.3M
EPS (TTM):
-$2.11
Analysts' Opinion
-
Consensus RatingVerve Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.11, Verve Therapeutics has an estimated upside of 37.97% from its current price of $10.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $10.95.
Fair Value
-
According to the consensus of 7 analysts, Verve Therapeutics has 37.97% upside to fair value with a price target of $15.11 per share.
VERV vs. S&P 500
-
Over the past 5 trading days, Verve Therapeutics has underperformed the S&P 500 by -1.59% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Verve Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Verve Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Verve Therapeutics reported revenues of $33M.
Earnings Growth
-
Verve Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Verve Therapeutics reported earnings per share of -$0.35.
Enterprise value:
479M
EV / Invested capital:
--
Price / LTM sales:
15.91x
EV / EBIT:
--
EV / Revenue:
8.04x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.26x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-26.95%
Net Income Margin (TTM):
-303.64%
Return On Equity:
-34.75%
Return On Invested Capital:
-34.75%
Operating Margin:
-111.1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | $16M | $59.6M | $5.7M | $33M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$192M | -$221.7M | -$208.5M | -$56.8M | -$36.6M | |
| EBITDA | -$188.6M | -$215.7M | -$201.6M | -$55.2M | -$34.9M | |
| Diluted EPS | -$3.14 | -$2.87 | -$2.11 | -$0.59 | -$0.35 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $151.8M | $328.8M | $517.8M | $620.3M | $511.7M | |
| Total Assets | $158.2M | $349.2M | $634.4M | $732.4M | $614.2M | |
| Current Liabilities | $6.7M | $14.8M | $33.6M | $31.3M | $52M | |
| Total Liabilities | $234.6M | $17.9M | $124.9M | $149.3M | $140.7M | |
| Total Equity | -$76.4M | $331.4M | $509.5M | $583.1M | $473.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$137.9M | -$143.5M | -$142.5M | -$43.1M | -$27.8M | |
| Cash From Investing | -$200.7M | -$29.3M | $68.3M | -$41.6M | -$48.2M | |
| Cash From Financing | $330.5M | $233.3M | $26.5M | $22.7M | $7K | |
| Free Cash Flow | -$151.6M | -$149.9M | -$147M | -$43.5M | -$29.1M | |
VERV
Sector
Market Cap
$976.1M
$34.4M
Price % of 52-Week High
96.01%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-5.98%
-1.01%
1-Year Price Total Return
45.81%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.04
200-day SMA
Buy
Level
$6.28
Bollinger Bands (100)
Buy
Level
3.86 - 9.04
Chaikin Money Flow
Sell
Level
-14.7M
20-day SMA
Sell
Level
$11.14
Relative Strength Index (RSI14)
Buy
Level
74.78
ADX Line
Sell
Level
41.49
Williams %R
Buy
Level
-93.9759
50-day SMA
Buy
Level
$7.54
MACD (12, 26)
Buy
Level
3.05
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Sell
Level
-19.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.1546)
Sell
CA Score
(Annual)
Level (-0.6319)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (1.1147)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Stock Forecast FAQ
In the current month, VERV has received 0 Buy ratings 7 Hold ratings, and 0 Sell ratings. The VERV average analyst price target in the past 3 months is $15.11.
-
Where Will Verve Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Verve Therapeutics share price will rise to $15.11 per share over the next 12 months.
-
What Do Analysts Say About Verve Therapeutics?
Analysts are divided on their view about Verve Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Verve Therapeutics is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Verve Therapeutics's Price Target?
The price target for Verve Therapeutics over the next 1-year time period is forecast to be $15.11 according to 7 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is VERV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Verve Therapeutics is a Hold. 7 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of VERV?
You can purchase shares of Verve Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Verve Therapeutics shares.
-
What Is The Verve Therapeutics Share Price Today?
Verve Therapeutics was last trading at $10.96 per share. This represents the most recent stock quote for Verve Therapeutics. Yesterday, Verve Therapeutics closed at $10.95 per share.
-
How To Buy Verve Therapeutics Stock Online?
In order to purchase Verve Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
72
SBET alert for Jul 18
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
